In addition, artesunate treatment resulted in a significant decrease in APP cleavage products, specifically CTF levels and soluble Aβ concentrations in the hippocampus homogenates of 12-month-old APP/PS1 mice, altogether supporting that artemisinins, especially artesunate, can not only prevent but eventually reverse the progression of amyloid deposition in the brain of APP/PS1 mice. This evidence concerns the gene APP and amyloidosis.